For the year ending 2025-12-31, RLYB had $17,471K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,978 |
| Depreciation and amortization | 92 |
| Net accretion of discounts/premiums on debt securities | -573 |
| Share-based compensation | 5,314 |
| Gain on sale of joint venture | 22,350 |
| Loss on investment in joint venture | -874 |
| Prepaid expenses, operating right-of-use assets and other current assets | 2,043 |
| Accounts payable | -152 |
| Accrued expenses and operating lease liabilities | -1,149 |
| Deferred revenue | -848 |
| Net cash used in operating activities | -29,813 |
| Purchases of marketable securities | 17,697 |
| Proceeds from maturities of marketable securities | 46,465 |
| Proceeds from sale of common stock received from sale of joint venture | 20,000 |
| Investment in joint venture | 1,500 |
| Net cash provided by investing activities | 47,268 |
| Proceeds from the issuance of common stock from a securities purchase agreement | 0 |
| Proceeds from the issuance of common stock under the stock purchase plan | 16 |
| Payments of offering costs | 0 |
| Net cash provided by financing activities | 16 |
| Net increase (decrease) in cash and cash equivalents | 17,471 |
| Cash and cash equivalentsbeginning of year | 13,903 |
| Cash and cash equivalentsend of year | 31,374 |
Rallybio Corp (RLYB)
Rallybio Corp (RLYB)